Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arbidol for COVID-19 Pneumonia
NCT04260594Phase 4Completed
- Start
- Feb 2020
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of umifenovir in COVID-19 pneumonia (2 arms). Primary endpoint: Virus negative conversion rate in the first week at 1 week. Started Feb 2020; status: completed.
02
Drugs
umifenovir
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04260594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04260594.